Log In
Print
BCIQ
Print
Print this Print this
 

IGN786

  Manage Alerts
Collapse Summary General Information
Company Igenica Inc.
DescriptionAntibody-drug conjugate
Molecular Target
Mechanism of ActionAntibody-drug conjugate
Therapeutic ModalityBiologic: Antibody-drug conjugate
Latest Stage of DevelopmentPreclinical
Standard IndicationChronic lymphocytic leukemia (CLL)
Indication DetailsTreat chronic lymphocytic leukemia (CLL)
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today